Stansky reports major TriSalus (TLSI) stock and warrant holdings on Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
TriSalus Life Sciences director Michael P. Stansky reported his existing ownership in a new Form 3 filing. He beneficially owns 543,232 shares of TriSalus common stock and a warrant exercisable for 827,500 shares of common stock at an exercise price of $11.50 per share, expiring on August 10, 2028.
The filing also reports 82,500 shares of common stock owned by Skyview Investments LLC, where Stansky is the managing member and exercises voting and dispositive power. All of these securities were acquired before he became a director, effective February 4, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Stansky Michael P
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrant | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Warrant — 827,500 shares (Direct);
Common Stock — 543,232 shares (Direct)
Footnotes (1)
- The securities reported herein were acquired by the Reporting Person prior to the Reporting Person becoming a director of the issuer. The Reporting Person was appointed as a director of the Issuer effective February 4, 2026. The securities reported herein are owned by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member.
FAQ
What insider holdings did Michael P. Stansky report in TriSalus Life Sciences (TLSI)?
Michael P. Stansky reported beneficial ownership of 543,232 TriSalus common shares and a warrant for 827,500 shares at $11.50 per share, expiring August 10, 2028. He also reported 82,500 shares held by Skyview Investments LLC, where he is managing member.
When did Michael P. Stansky become a director of TriSalus Life Sciences (TLSI)?
Michael P. Stansky became a director of TriSalus Life Sciences effective February 4, 2026. The Form 3 notes that all reported securities, including common stock and warrants, were acquired before his appointment as a director of the company on that effective date.
What warrant position did Michael P. Stansky disclose for TriSalus Life Sciences (TLSI)?
He disclosed a warrant covering 827,500 shares of TriSalus common stock with an exercise price of $11.50 per share. The warrant became exercisable on August 10, 2023 and is scheduled to expire on August 10, 2028, according to the Form 3.
Did Michael P. Stansky acquire his TriSalus (TLSI) securities after joining the board?
No. The Form 3 states the securities were acquired before he became a director. His appointment as a director became effective on February 4, 2026, and the filing simply reports his existing ownership positions as of that date.